KIGEN
10.8.2021 15:02:15 CEST | Business Wire | Press release
AT&T and Kigen are working together to help customers streamline their supply chains and reduce the time to market for enterprises who want to leverage SIM, embedded SIM (eSIM) and integrated SIM (iSIM) secured connectivity deep in their IoT devices.
Kigen’s SIM OS, data generation and key management services will allow AT&T to offer a broader selection for integrated SIM solutions. Manufacturers will enjoy greater flexibility by sourcing their AT&T SIM at the stage of the device manufacturing process that best suits the customer. This might be at the point of contract manufacturing, module supply, or even at the chipset level by leveraging an integrated SIM and merging both chip and SIM into a single component.
Reducing complexity and accelerating time to market will attract new customers that are embarking on their cellular IoT transformation, or those that are accelerating the adoption of secure connected goods and bringing them to market sooner as a result of streamlining the chipset and SIM evaluation process.
Prior to this, device manufacturers had to purchase multiple SIM SKUs for each end-customer or market, which has complicated global product rollouts. Access to a new cache of SIMs that are compatible with cellular chipsets and secure IC vendors offers additional flexibility that results in supply chain optimisation. This streamlined approach also simplifies the manufacturing process by allowing suppliers, OEMs and licensees to identify the ideal SIM solution earlier in the design process, meaning device estates can scale sooner upon deployment.
Kigen’s SIM OS, data generation, and key management services will enable seamless access to AT&T’s Network across LTE, LTE-M, and NB-IoT technologies. Simple integration makes it easier for new entrants and established players alike to adopt cellular IoT in their devices sooner while futureproofing them with 5G readiness.
“By working with Kigen we can help enable device manufacturers to streamline their IoT device development and manufacturing.” Said William Stovall, vice president, Mobility, IoT and 5G, AT&T. “This collaboration will also offer AT&T customers the ability to bring more innovative and secure features to market sooner.”
“Scale is both cellular IoT’s most significant opportunity and hurdle. Removing the complications of placing security at the heart of IoT devices so that businesses can focus on accelerating their products is key,” said Vincent Korstanje, CEO, Kigen. “The combination of Kigen’s solutions across all types of SIM from our ecosystem with AT&T’s connectivity simplifies how businesses choose the right type of security, tuned to their manufacturing needs; offering trusted IoT that scales.”
About Kigen
At Kigen, we are making the future of securing connectivity simple. As simple as can be. As a wholly owned subsidiary of Arm, together with our partners and customers, we are unlocking new opportunities as (integrated) eSIM becomes the cornerstone of connected devices security. Our industry-leading SIM OS products enable over 2 billion SIMs. Our remote SIM provisioning and eSIM services drive this momentum further placing us amongst top 5 SIM vendors globally. Our 135 employees globally are guided by the vision of a world where every device can connect securely and reliably. For more information, go to kigen.com or speak to us on @Kigen_Ltd on Twitter and LinkedIn about #futureofSIM.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom